The present invention relates generally to fluid cooling devices. More particularly, the present invention relates to the cooling of fluids by endothermic reaction.
The cooling of core body temperature, such as for inducing hypothermia, is a medical treatment increasingly being used to treat patients as part of various medical-related procedures. Administering cooled intravenous fluids to induce hypothermia in cardiac arrest patients in the pre-hospital setting has been found to improve the likelihood of those patients being subsequently discharged from the hospital neurologically intact. Induced hypothermia therapy has proven effective in postponing damage to tissues caused by insufficient blood flow and oxygen deprivation. The smaller the time difference between cardiac arrest and induced hypothermia, the higher the likelihood of successful treatment. While there are in-hospital products available for inducing hypothermia, these products are not feasible for use in the pre-hospital setting.
The cooling of intravenous fluids for use in the pre-hospital setting is currently achieved though the use of conventional, bulky refrigeration units or simply ice-filled containers. Primary responders are typically unable to carry both conventional refrigerators and cardiac arrest patients simultaneously on-board a vehicle (e.g., ambulance, helicopter, etc.), or at least it is impractical to do so, for various reasons such as the space required for the refrigeration unit or ice-filled container and the fact that induced hypothermia as a treatment will be indicated in only a small fraction of the emergency situations encountered. Consequently, a second emergency vehicle carrying a refrigeration unit is required to intercept the primary responder and supply the primary responder with cooled intravenous fluids to administer to the patient. Once the cooled fluids are taken out of the refrigerator or ice-filled container, the fluids immediately begin to warm and there is currently no method available to effectively stop the warming process.
In recent years, there has been evidence supporting the use of induced hypothermia therapy in various other medical applications, including cardiac surgery and stroke recovery. As more medical discoveries are made, the potential uses of cooled fluids are likely to increase in both the pre-hospital and in-hospital settings.
In view of the foregoing, there is an ongoing need for cost-effective, efficient, portable, and compact fluid cooling devices for use in the medical field in general, and for use in rapidly cooling intravenous fluids in particular such as for inducing hypothermia in patients requiring medical attention, as well as for use in various non-medical fields.
To address the foregoing problems, in whole or in part, and/or other problems that may have been observed by persons skilled in the art, the present disclosure provides methods, processes, systems, apparatus, instruments, and/or devices, as described by way of example in implementations set forth below.
According to one implementation, a cooling device includes a target fluid inlet, a target fluid outlet, an inner conduit, and a chamber surrounding the inner conduit. The inner conduit fluidly communicates with the target fluid inlet and the target fluid outlet, and provides a flow path for a target fluid to be cooled. The chamber surrounding the inner conduit contains a first endothermic reactant and includes a reactant inlet selectively alterable from a closed state to an open state. When the reactant inlet is in the closed state, the first endothermic reactant is isolated from a second endothermic reactant and no endothermic reaction occurs. When the reactant inlet is in the open state, the reactant inlet provides a flow path for enabling the second endothermic reactant to come into contact with the first endothermic reactant in the chamber for initiating the endothermic reaction and cooling the target fluid in the inner conduit.
According to another implementation, the reactant inlet of the cooling device may further include a barrier. When the reactant inlet is in the closed state, the barrier may divide the chamber into a first region containing the first endothermic reactant, and a second region containing the second endothermic reactant. The cooling device may include an actuator configured to open the barrier wherein the reactant inlet is altered to the open state.
According to another implementation, the cooling device includes a pressure release valve adapted to communicate with the chamber, wherein the pressure release valve allows flow from the chamber to a receptacle adapted to communicate with the pressure release valve when the pressure in the chamber increases to a predetermined critical pressure.
According to another implementation, at least a portion of the chamber is flexible such that the volume of the chamber is expandable.
According to another implementation, the cooling device includes an insulating material surrounding the chamber.
According to another implementation, the target fluid includes saline solution. In another implementation, the target fluid further includes a therapeutically active drug.
According to another implementation, the reactant inlet comprises a fitting configured for connection to an external source of the second endothermic reactant. In another implementation, the reactant inlet comprises a valve.
According to another implementation, an intravenous target fluid delivery system includes an IV target fluid reservoir, a cooling device, and a cooled IV target fluid receiving tube. The IV target fluid reservoir contains an IV target fluid to be cooled in the cooling device. The IV target fluid reservoir fluidly communicates with a target fluid inlet of the cooling device. The cooled IV target fluid receiving tube fluidly communicates with a target fluid outlet of the cooling device, and is configured for intravenously administering the cooled IV target fluid to a patient.
According to another implementation, the first endothermic reactant includes an inorganic salt such as, for example, ammonium nitrate, ammonium chloride, potassium chloride, etc. The second endothermic reactant may, for example, include water.
According to another implementation, the reactant inlet includes a barrier and in the closed state, the barrier divides the chamber into a first region containing the first endothermic reactant, and a second region containing the second endothermic reactant. In some implementations, an actuator is configured to open the barrier wherein the reactant inlet is altered to an open state. The actuator may be configured to puncture the barrier. Alternatively, the actuator may be configured to move at least a portion of the barrier to create an opening therethrough.
In some implementations, the IV target fluid reservoir may include an IV bag. The cooled IV target fluid receiving tube may include an IV catheter.
According to another implementation, a method is provided for cooling a target fluid. In the method, a target fluid is flowed from a target fluid inlet of a cooling device, through the cooling device, and to a target fluid outlet of the cooling device. While flowing the target fluid, heat is removed from the target fluid by conducting an endothermic reaction in the cooling device.
According to another implementation, a method is provided for treating a patient. A target fluid to be cooled is flowed from a reservoir through a target fluid inlet of a cooling device, and into an inner conduit of the cooling device. The cooling device includes a chamber surrounding the inner conduit and containing a first endothermic reactant. The chamber includes a reactant inlet selectively alterable from a closed state to an open state, wherein in the closed state, the first endothermic reactant is isolated from a second endothermic reactant and no endothermic reaction occurs. The endothermic reaction is initiated and the target fluid in the inner conduit is cooled by altering the reactant inlet from the closed state to the open state, wherein the reactant inlet provides a flow path for enabling the second endothermic reactant to come into contact with the first endothermic reactant in the chamber. The cooled target fluid is flowed through a target fluid outlet of the cooling device into a cooled-fluid-receiving tube. The cooled target fluid is administered to the patient intravenously to reduce the patient's core body temperature.
In some implementations, the target fluid includes saline solution. In further implementations, the target fluid further comprises a therapeutically active drug.
Other devices, apparatus, systems, methods, features and advantages of the invention will be or will become apparent to one with skill in the art upon examination of the following figures and detailed description. It is intended that all such additional systems, methods, features and advantages be included within this description, be within the scope of the invention, and be protected by the accompanying claims.
The invention can be better understood by referring to the following figures. The components in the figures are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention. In the figures, like reference numerals designate corresponding parts throughout the different views.
By way of example,
As appreciated by persons skilled in the art, various types of endothermic reactions exist and thus the specific reactants utilized in the cooling device 100 will depend on the particular endothermic reaction being implemented. As examples, ammonium nitrate, ammonium chloride, or potassium chloride may be utilized as the first endothermic reactant, and in each case, water may be utilized as the flowable second endothermic reactant. Other flowable materials may also be suitable for serving as the second endothermic reactant. Generally, the cooling device 100 may employ any combination of reactants that, when combined, result in an endothermic reaction suitable for rapid cooling of a selected target fluid such as, for example, saline solution. The second endothermic reactant may be flowed into the chamber 106 via the reactant inlet 108 by any suitable means such as, for example, utilizing a syringe (not shown) or other external source of reactant. Alternatively, the second endothermic reactant may be provided internally within the cooling device as described by example below in conjunction with
In the present example, the chamber 106 may be constructed of, for example, PVC plastic. At each end of the chamber 106, an end plate 110 may be attached to the chamber 106 by any suitable means, and may be constructed to accommodate the ends of the inner conduits. An end cap 112 may also be secured by any suitable means to the end plate 110 and/or chamber 106 at each end of the chamber 106. The end caps 112 may be tapered or otherwise configured to accommodate the positions of the inner conduit(s) and/or the flow transitions between the inner conduit(s) of the chamber 106 and the target fluid inlet 102 and target fluid outlet 104. Both the end plates 110 and the end caps 112 may be constructed of, for example, ABS plastic. In some implementations, a pressure release valve 114 may optionally be provided to communicate with the chamber 106 such that pressure may release from the chamber 106 to, for example, a receptacle (not shown) adapted to communicate with the pressure release valve 114 when the pressure in the chamber 106 increases to a predetermined critical pressure. For example, if a syringe is used to admit the second endothermic reactant into the chamber 106 via the reactant inlet 108, the pressure release valve 114 may be used to release any excess pressure in the chamber 106 resulting from utilization of the syringe. The use of a receptacle at the pressure release valve 114 maintains the cooling device 100 as a closed system and ensures that the endothermic reactants remain isolated from the environment. Alternatively, element 114 may represent a fluid connection to a flexible chamber that allows for expansion. As a further alternative, at least a portion of the chamber 106 may be flexible to allow for expansion. The chamber 106 may also be surrounded by an insulating material (e.g., polypropylene foam covered in vinyl fabric) to ensure a minimum amount of heat transfer into the cooling device 100 from the outside environment.
The cooling device 100 in
In the present example, the inner helical conduits 216 may be constructed of a thermally conductive material providing adequate heat transfer such as, for example, various metals, e.g., stainless steel, titanium, aluminum, or brass, and certain thermally conductive plastics. In some implementations, the inner helical conduits 216 may be constructed of medical grade conductive materials to ensure against contamination of the target fluid for medical uses. If needed, the inside and/or outside surfaces of the inner helical conduits 216 may be coated with biocompatible or protective barrier films, as appreciated by persons skilled in the art. When the cooling device 100 is assembled, an end plate 110 may be attached to the chamber 106 at each end of the chamber 106, and may be constructed to accommodate the ends of the inner helical conduits 216 and support the inner helical conduits 216 in the chamber 106 in a fixed manner. For instance, in the present example in which three inner helical conduits 216 are utilized, each end plate 110 may include three through-bores respectively communicating with the three inner helical conduits 216 to facilitate flow-splitting from the target fluid inlet 102 and flow-merging to the target fluid outlet 104. An end cap 112 may also be secured by any suitable means (e.g., through the use of an adhesive) to the outside of the end plate 110 and/or the chamber 106 at each end of the chamber 106 when the cooling device 100 is assembled. As also noted above, the chamber 106 may also be surrounded by an insulating material (not specifically shown) to ensure a minimum amount of heat transfer into the cooling device 100 from the outside environment.
In the present example, the barrier 420 may be opened by any suitable user-actuated opening mechanism 424. For example, the mechanism 424 may include a button or knob that, when actuated by the user (e.g., pressed, pulled, slid, rotated, etc.), actuates a puncturing device 438 that breaks the barrier 420 and hence alters the reactant inlet 414 to the open state by creating the opening 440, which allows the first and second endothermic reactants to mix or combine within the chamber 106. As used herein, terms such as “mix” and “combine” encompass any type of contact or interaction between reactants that results in the endothermic reaction utilized as the cooling mechanism according to the present teachings. The exact mechanics of the interaction between the endothermic reactants and the particular reaction kinetics will depend on the type of endothermic reaction conducted in a given implementation, one non-limiting example being the dissolution of certain nitrates or chlorides in a suitable solvent such as water as noted above. As another example, the mechanism 424 may include or operate as a switch that, when actuated by the user, moves the barrier 420 or a portion thereof (e.g., a valve, shutter, or sliding mechanism) to an open state, thereby creating the opening 440 and allowing the second endothermic reactant to flow. In this latter case, the element 438 may represent any suitable mechanical linkage between the mechanism 424 and the barrier 420. For instance, the mechanism 424 may be linked to the barrier 420 such that pushing or pulling the mechanism 424 translates or rotates all or part of the barrier 420 to create the opening 440. As another alternative, the mechanism 424 may be configured such that sliding the mechanism 424 a short distance causes the barrier 420 to open in the manner of a shutter. In all of the foregoing alternatives, the term “breaking” as used in conjunction with altering the barrier 420 encompasses any means by which the opening 440 may be created (e.g., puncturing, moving the barrier 420 or a portion thereof, etc.), and thus in this context terms such as “breaking” and “opening” are used interchangeably. Moreover, in conjunction with breaking or opening the barrier 420, the cooling device 400 may be shaken or agitated by the user to promote the mixing of the reactants.
In general, terms such as “communicate” and “in . . . communication with” (for example, a first component “communicates with” or “is in communication with” a second component) are used herein to indicate a structural, functional, mechanical, electrical, signal, optical, magnetic, electromagnetic, ionic or fluidic relationship between two or more components or elements. As such, the fact that one component is said to communicate with a second component is not intended to exclude the possibility that additional components may be present between, and/or operatively associated or engaged with, the first and second components.
It will be understood that various aspects or details of the invention may be changed without departing from the scope of the invention. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation—the invention being defined by the claims.
This application claims the benefit of U.S. Provisional Patent Application Ser. No. 61/154,972, filed Feb. 24, 2009, titled “RAPID FLUID COOLING DEVICES AND METHODS FOR COOLING FLUIDS;” the content of which is incorporated by reference herein in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
4065235 | Furlong et al. | Dec 1977 | A |
4522640 | Jagoe, III | Jun 1985 | A |
4528218 | Maione | Jul 1985 | A |
4653577 | Noda | Mar 1987 | A |
4697636 | Mellsjo | Oct 1987 | A |
4705505 | Fried | Nov 1987 | A |
4751119 | Yukawa | Jun 1988 | A |
4758562 | Adler et al. | Jul 1988 | A |
4986076 | Kirk et al. | Jan 1991 | A |
4993237 | Bond et al. | Feb 1991 | A |
5062269 | Siegel | Nov 1991 | A |
5088302 | Tomizawa et al. | Feb 1992 | A |
5219274 | Pawlowski et al. | Jun 1993 | A |
5263929 | Falcone et al. | Nov 1993 | A |
5395314 | Klatz et al. | Mar 1995 | A |
5429762 | Kitahara et al. | Jul 1995 | A |
5494416 | Gergets | Feb 1996 | A |
5752929 | Klatz et al. | May 1998 | A |
5827222 | Klatz et al. | Oct 1998 | A |
5840068 | Cartledge | Nov 1998 | A |
5913885 | Klatz et al. | Jun 1999 | A |
6019783 | Philips et al. | Feb 2000 | A |
6033383 | Ginsburg | Mar 2000 | A |
6035102 | Bakke | Mar 2000 | A |
6042559 | Dobak, III | Mar 2000 | A |
6051019 | Dobak, III | Apr 2000 | A |
6056932 | Von Hippel et al. | May 2000 | A |
6076597 | Manning et al. | Jun 2000 | A |
6090132 | Fox | Jul 2000 | A |
6096068 | Dobak, III et al. | Aug 2000 | A |
6110168 | Ginsburg | Aug 2000 | A |
6149624 | McShane | Nov 2000 | A |
6149670 | Worthen et al. | Nov 2000 | A |
6149676 | Ginsburg | Nov 2000 | A |
6149677 | Dobak, III | Nov 2000 | A |
6158994 | Mulcahy | Dec 2000 | A |
6224624 | Lasheras et al. | May 2001 | B1 |
6231594 | Dae | May 2001 | B1 |
6231595 | Dobak, III | May 2001 | B1 |
6233945 | Kohout | May 2001 | B1 |
6264679 | Keller et al. | Jul 2001 | B1 |
6270324 | Sullivan et al. | Aug 2001 | B1 |
6306161 | Ginsburg | Oct 2001 | B1 |
6440158 | Saab | Aug 2002 | B1 |
6454792 | Noda et al. | Sep 2002 | B1 |
6478812 | Dobak, III et al. | Nov 2002 | B2 |
6527798 | Ginsburg et al. | Mar 2003 | B2 |
6547811 | Becker et al. | Apr 2003 | B1 |
6554791 | Cartledge et al. | Apr 2003 | B1 |
6572640 | Balding et al. | Jun 2003 | B1 |
6582455 | Dobak, III et al. | Jun 2003 | B1 |
6607517 | Dae et al. | Aug 2003 | B1 |
6620131 | Pham et al. | Sep 2003 | B2 |
6623514 | Chin | Sep 2003 | B1 |
6656209 | Ginsburg | Dec 2003 | B1 |
6702839 | Dae et al. | Mar 2004 | B1 |
6736790 | Barbut et al. | May 2004 | B2 |
6752786 | Callister | Jun 2004 | B2 |
6878156 | Noda | Apr 2005 | B1 |
6905509 | Dobak, III et al. | Jun 2005 | B2 |
6939520 | Filippi et al. | Sep 2005 | B2 |
6962601 | Becker et al. | Nov 2005 | B2 |
7008444 | Dae et al. | Mar 2006 | B2 |
7008445 | Lennox | Mar 2006 | B2 |
7014651 | Worthen et al. | Mar 2006 | B2 |
7052509 | Lennox et al. | May 2006 | B2 |
7077825 | Stull | Jul 2006 | B1 |
7144418 | Lennox | Dec 2006 | B1 |
7231771 | McMurry et al. | Jun 2007 | B2 |
7303328 | Faraldi et al. | Dec 2007 | B2 |
7311724 | Ginsburg | Dec 2007 | B1 |
7350361 | Maxwell et al. | Apr 2008 | B2 |
7422600 | Dobak | Sep 2008 | B2 |
7422601 | Becker et al. | Sep 2008 | B2 |
7449018 | Kramer | Nov 2008 | B2 |
7507250 | Lennox | Mar 2009 | B2 |
7571621 | Dietschi et al. | Aug 2009 | B2 |
7597136 | Kite et al. | Oct 2009 | B2 |
7758623 | Dzeng et al. | Jul 2010 | B2 |
7806915 | Scott et al. | Oct 2010 | B2 |
7827815 | Carson et al. | Nov 2010 | B2 |
7867266 | Collins | Jan 2011 | B2 |
7989508 | Hecht | Aug 2011 | B2 |
8047010 | Carson et al. | Nov 2011 | B2 |
8091337 | Tepesch | Jan 2012 | B2 |
8100123 | Belson | Jan 2012 | B2 |
8117854 | Lampe et al. | Feb 2012 | B2 |
8157794 | Dobak et al. | Apr 2012 | B2 |
8231664 | Kulstad et al. | Jul 2012 | B2 |
8257340 | Saab | Sep 2012 | B2 |
8308787 | Kreck | Nov 2012 | B2 |
8343202 | Magers | Jan 2013 | B2 |
8388571 | Joshi et al. | Mar 2013 | B2 |
8388578 | Joshi et al. | Mar 2013 | B2 |
8402968 | Belson | Mar 2013 | B2 |
8409265 | Keller et al. | Apr 2013 | B2 |
8439960 | Burnett et al. | May 2013 | B2 |
20010001830 | Dobak et al. | May 2001 | A1 |
20010001831 | Dobak et al. | May 2001 | A1 |
20010007951 | Dobak, III | Jul 2001 | A1 |
20010016763 | Lasheras et al. | Aug 2001 | A1 |
20020004675 | Lasheras | Jan 2002 | A1 |
20020045852 | Saab | Apr 2002 | A1 |
20020082671 | Magers et al. | Jun 2002 | A1 |
20020095201 | Worthen et al. | Jul 2002 | A1 |
20020111584 | Walker et al. | Aug 2002 | A1 |
20020111657 | Dae et al. | Aug 2002 | A1 |
20020116039 | Walker et al. | Aug 2002 | A1 |
20020138122 | Worthen et al. | Sep 2002 | A1 |
20020151845 | Werneth | Oct 2002 | A1 |
20020151942 | Walker et al. | Oct 2002 | A1 |
20020151944 | Pham et al. | Oct 2002 | A1 |
20020161349 | Allers et al. | Oct 2002 | A1 |
20020161351 | Samson et al. | Oct 2002 | A1 |
20020183816 | Tzeng et al. | Dec 2002 | A1 |
20020198579 | Khanna | Dec 2002 | A1 |
20030004456 | Saab | Jan 2003 | A1 |
20030060761 | Evans et al. | Mar 2003 | A1 |
20030078641 | Dobak, III | Apr 2003 | A1 |
20030130651 | Lennox | Jul 2003 | A1 |
20030139791 | Dobak, III | Jul 2003 | A1 |
20030216746 | Worthen et al. | Nov 2003 | A1 |
20040073280 | Dae et al. | Apr 2004 | A1 |
20040158191 | Samson et al. | Aug 2004 | A1 |
20040199114 | Noda | Oct 2004 | A1 |
20040199229 | Lasheras | Oct 2004 | A1 |
20040210281 | Dzeng et al. | Oct 2004 | A1 |
20040215163 | Walker et al. | Oct 2004 | A1 |
20040215297 | Collins | Oct 2004 | A1 |
20040220647 | Noda | Nov 2004 | A1 |
20050004503 | Samson et al. | Jan 2005 | A1 |
20050027244 | Eidenschink | Feb 2005 | A1 |
20050027281 | Lennox | Feb 2005 | A1 |
20050033391 | Worthen et al. | Feb 2005 | A1 |
20050076924 | Dobak, III | Apr 2005 | A1 |
20050080374 | Esch et al. | Apr 2005 | A1 |
20050096714 | Freedman et al. | May 2005 | A1 |
20050107741 | Harrison et al. | May 2005 | A1 |
20050120734 | Yon | Jun 2005 | A1 |
20050274118 | McMurry et al. | Dec 2005 | A1 |
20060064146 | Collins | Mar 2006 | A1 |
20060136023 | Dobak, III | Jun 2006 | A1 |
20060142827 | Willard et al. | Jun 2006 | A1 |
20060161232 | Kasza et al. | Jul 2006 | A1 |
20060167398 | Solar et al. | Jul 2006 | A1 |
20060184231 | Rucker | Aug 2006 | A1 |
20060293732 | Collins et al. | Dec 2006 | A1 |
20070000278 | Collins et al. | Jan 2007 | A1 |
20070005121 | Khanna | Jan 2007 | A1 |
20070050002 | Elefteriades | Mar 2007 | A1 |
20070191918 | MacHold et al. | Aug 2007 | A1 |
20070244434 | Noda et al. | Oct 2007 | A1 |
20070244531 | Noda et al. | Oct 2007 | A1 |
20070293921 | Noda et al. | Dec 2007 | A1 |
20080027383 | Nahhas | Jan 2008 | A1 |
20080046046 | Ginsburg | Feb 2008 | A1 |
20080114431 | Ginsburg | May 2008 | A1 |
20080221651 | Dobak | Sep 2008 | A1 |
20080271476 | Langguth | Nov 2008 | A1 |
20080296190 | Marak et al. | Dec 2008 | A1 |
20090265113 | Kimball | Oct 2009 | A1 |
20100030190 | Singh | Feb 2010 | A1 |
20100104493 | Hyde et al. | Apr 2010 | A1 |
20100121159 | Burnett et al. | May 2010 | A1 |
20100160705 | Kosters | Jun 2010 | A1 |
20100204765 | Hall et al. | Aug 2010 | A1 |
20100324483 | Rozenberg et al. | Dec 2010 | A1 |
20110029050 | Elefteriades et al. | Feb 2011 | A1 |
20110066217 | Diller et al. | Mar 2011 | A1 |
20110082423 | Joshi et al. | Apr 2011 | A1 |
20110125233 | Shen et al. | May 2011 | A1 |
20110137248 | Winter | Jun 2011 | A1 |
20110137249 | Collins et al. | Jun 2011 | A1 |
20120095536 | Machold et al. | Apr 2012 | A1 |
20120095537 | Hall et al. | Apr 2012 | A1 |
20120116487 | Burnett et al. | May 2012 | A1 |
20120123509 | Merrill et al. | May 2012 | A1 |
20120172781 | Wang | Jul 2012 | A1 |
20120221082 | Khanna | Aug 2012 | A1 |
20130030411 | Kreck et al. | Jan 2013 | A1 |
20130046232 | Walker et al. | Feb 2013 | A1 |
20130046365 | Noda et al. | Feb 2013 | A1 |
20130060311 | Noda et al. | Mar 2013 | A1 |
Number | Date | Country |
---|---|---|
199946852 | Jan 2000 | AU |
2007201161 | Apr 2007 | AU |
2538331 | Mar 2003 | CN |
102309786 | Jan 2012 | CN |
1028679 | Aug 2000 | EP |
1049412 | Nov 2000 | EP |
1205167 | May 2002 | EP |
1406566 | Apr 2004 | EP |
2514453 | Oct 2012 | EP |
1245824 | May 1992 | IT |
2008154751 | Jul 2008 | JP |
04610825 | Jan 2011 | JP |
0009054 | Feb 2000 | WO |
0010494 | Mar 2000 | WO |
0047145 | Aug 2000 | WO |
0053135 | Sep 2000 | WO |
0057823 | Oct 2000 | WO |
0059419 | Oct 2000 | WO |
0062837 | Oct 2000 | WO |
0110323 | Feb 2001 | WO |
0110365 | Feb 2001 | WO |
0112061 | Feb 2001 | WO |
0126590 | Apr 2001 | WO |
0136035 | May 2001 | WO |
0141708 | Jun 2001 | WO |
0143661 | Jun 2001 | WO |
0149236 | Jul 2001 | WO |
0152781 | Jul 2001 | WO |
0156517 | Aug 2001 | WO |
0158397 | Aug 2001 | WO |
0166052 | Sep 2001 | WO |
0174276 | Oct 2001 | WO |
0195840 | Dec 2001 | WO |
0226176 | Apr 2002 | WO |
0226285 | Apr 2002 | WO |
0228458 | Apr 2002 | WO |
0236180 | May 2002 | WO |
0238091 | May 2002 | WO |
02058606 | Aug 2002 | WO |
02068928 | Sep 2002 | WO |
03015672 | Feb 2003 | WO |
03015673 | Feb 2003 | WO |
03028796 | Apr 2003 | WO |
03037158 | May 2003 | WO |
03066137 | Aug 2003 | WO |
2004023982 | May 2004 | WO |
2004075949 | Sep 2004 | WO |
2005112843 | Dec 2005 | WO |
2007002946 | Jan 2007 | WO |
2007005026 | Jan 2007 | WO |
2007078463 | Jul 2007 | WO |
2009023797 | Feb 2009 | WO |
2009094601 | Jul 2009 | WO |
2009102803 | Aug 2009 | WO |
2009124552 | Oct 2009 | WO |
2009124553 | Oct 2009 | WO |
2010111778 | Oct 2010 | WO |
2011103208 | Aug 2011 | WO |
2011156565 | Dec 2011 | WO |
2012006184 | Jan 2012 | WO |
2012012740 | Jan 2012 | WO |
2013049637 | Apr 2013 | WO |
Entry |
---|
Hypothermia after Cardiac Arrest Study Group, (2002), Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. The New England Journal of Medicine, 346(8), 549-556. |
Bernard, S.A., Gray, T.W., Buist, M.D., Jones, B.M., Silvester, W., Guthridge, G., et al. (2002), Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. The New England Journal of Medicine, 346(8), 557-563. |
Keller, E. Imhof, Ho G., Gasser, S., Terzic, A., & Yonekawa, Y. (2003). Endovascular cooling with heat exchange catheters: A new method to induce and maintain hypothermia. Intensive Care Medicine, 29(6), 939-943. |
Nolan, J.P., Morley, P.T., Hock, T.L., Hicking, R.W., & Advancement Life Support Task Force of the International Liaison Committee on Resuscitation. (2003). Therapuetic hypothermia after cardiac arrest. An advisory statement by the advancement life support task force of the international liaison committee on resuscitation. Resuscitation, 57(3), 231-235. |
Al-Senani, F.M., Grattagnino, C., Grotta, J.C., Saiki, R., Wood, D., Chung, W., et al. (2004). A prospective, multicenter pilot study to evaluate the feasibility and safety of using the CoolCard(tm) system and Icy(tm) catheter following cardiac arrest. Resuscitation, 62(2), 143-150. |
Diringer, M.N., & Neurocritical Care Fever Reduction Trial Group (2004). Treatment of fever in the neurologic intensive care unit with a catheter-based heat exchange system, Critical Care Medicine, 32(2), 559-564. |
Huppman, S., Johnson, J. Kang, S. & Wacker, E.; Intravenous Cooling System to Induce Mild Hypothermia; University of Pitsburgh Senior Design, BioE 1160-1161; Apr. 10, 2007, 27 pages. |
Huppman, S., Johnson, J. Kang, S. & Wacker, E.; IV Cooling System for Hypothermia, SBIR Proposal; Apr. 17, 2007; 22 pages. |
Number | Date | Country | |
---|---|---|---|
61154972 | Feb 2009 | US |